Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 8;10(2):ofad059. doi: 10.1093/ofid/ofad059

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 2. — Heat maps depicting overall treatment response up to 18-month follow-up after initiation of antifungal treatment for the nonsurvivor subgroup with Lomentospora prolificans infection (n = 26; A) and the survivor subgroup with L prolificans infection (n = 11; B). Cases 24, 32, and 37 were lost to follow-up. A cutoff of ±1.5 months around each follow-up time point was used to allow for the fact that follow-up visits may not be conducted at exactly each time point given the retrospective study design. Immunosuppression level: high (H; eg, hematological malignancy [HM], hematopoietic stem cell transplant [HSCT]); moderate (M; eg, solid organ transplant [SOT], immunosuppressed for reasons other than HM/HSCT and SOT); or low/no (L; eg, minor/no medical condition).